アブストラクト
Japanese
| Title | がん遺伝子パネル検査 (がんゲノムプロファイリング検査) |
|---|---|
| Subtitle | 〔特集〕膵疾患の病理学的診断の現状と課題 |
| Authors | 林秀幸, 西原広史* |
| Authors (kana) | |
| Organization | *慶應義塾大学医学部腫瘍センターゲノム医療ユニット |
| Journal | 膵臓 |
| Volume | 35 |
| Number | 4 |
| Page | 313-321 |
| Year/Month | 2020 / |
| Article | 報告 |
| Publisher | 日本膵臓学会 |
| Abstract | 「要旨」: 本邦においてもがん遺伝子パネル検査(がんゲノムプロファイリング検査)が保険診療下で実施可能となり, がんゲノム医療の臨床実装が進んでいる. 個々の患者にとって最適な治療方針を探るための参考情報として, 包括的なゲノムプロファイルを取得することが検査の本来の目的である. しかし, 現状では保険適用での対象患者は標準治療がない固形がん患者, または標準治療が終了となった固形がん患者(終了が見込まれる者を含む)で, 全身状態・臓器機能等から検査後に化学療法の適応となる可能性が高い患者に限定されており, 十分に活用できてない. 検査の結果に関しては, エキスパートパネルにおいて検出された各遺伝子異常に対し, 臨床的意義付けが行われ, 個々の患者の治療方針が議論される. しかし, 検査後の治療実施率は約10%と不十分な結果であり, 最適な検査実施時期の検討, 治療機会の向上を目指した治療実施体制を構築することが今後の課題である. |
| Practice | 臨床医学：内科系 |
| Keywords | 遺伝子解析, クリニカルシークエンス, ゲノム医療, 個別化治療, プレシジョンメディシン, Clinical sequencing, Genomic analysis, Genome medicine, Personalized medicine, Precision medicine |
English
| Title | Cancer genomic profiling |
|---|---|
| Subtitle | |
| Authors | Hideyuki HAYASHI, Hiroshi NISHIHARA* |
| Authors (kana) | |
| Organization | *Genomics Unit, Keio Cancer Center, Keio University School of Medicine |
| Journal | Journal of the Japan Pancreas Society |
| Volume | 35 |
| Number | 4 |
| Page | 313-321 |
| Year/Month | 2020 / |
| Article | Report |
| Publisher | Japan Pancreas Society |
| Abstract | Clinical implementation of cancer genomic medicine using the cancer genomic profiling test reimbursed by national health insurance is proceeding in Japan. The principal purpose of the study is to obtain useful genomic profiles for the treatment of patients with cancer. Performing the cancer genomic profiling test under the health insurance system is only for patients with cancer with no standard chemotherapy, such as certain rare malignancies and cancer of unknown primary. This also includes patients with already well-treated solid tumors who would be expected to have a good performance status even after the cancer genomic profiling test. The results of the genomic profile and treatment strategies based on genomic information for patients are discussed in the conference by an expert panel. However, only about 10% of patients can eventually receive genotype-matched treatment based on the results of the cancer genomic profiling test based on the current system in Japan. For the maximum utilization of data from the cancer genomic profiling test, we have to consider the proper timing to perform it and develop an accessible system for taking genotype-matched treatment including off-label use of various anticancer agents. |
| Practice | Clinical internal medicine |
| Keywords | Clinical sequencing, Genomic analysis, Genome medicine, Personalized medicine, Precision medicine |
- 全文ダウンロード： 従量制、基本料金制の方共に770円(税込) です。
参考文献
- 1) Sunami K, Ichikawa H, Kubo T, et al. Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting: a hospital-based study. Cancer Sci 2019; 110: 1480-90.
- 2) Schwaederle M, Daniels GA, Piccioni DE, et al. On the road to precision cancer medicine: analysis of genomic biomarker actionability in 439 patients. Mol Cancer Ther 2015; 14: 1488-94.
- 3) Bonneville R, Krook MA, Kautto EA, et al. Landscape of microsatellite instability across 39 cancer types.JCO Precis Oncol 2017; 2017: 10.1200/PO.17.00073.
- 4) Okamura R, Boichard A, Kato S, Sicklick JK, Bazhenova L, Kurzrock R. Analysis of NTRK alterations in pan-cancer adult and pediatric malignancies: implications for NTRK-targeted therapeutics. JCO Precis Oncol 2018; 2018: 10.1200/PO.18.00183.
- 5) Zehir A, Benayed R, Shah RH, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med 2017;23: 703-13.
残りの7件を表示する
- 6) Tanabe Y, Ichikawa H, Kohno T, et al. Comprehensive screening of target molecules by next-generation sequencing in patients with malignant solid tumors :guiding entry into phase I clinical trials. Mol Cancer 2016; 15: 73.
- 7) Kalia SS, Adelman K, Bale SJ, et al. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0):a policy statement of the American College of Medical Genetics and Genomics. Genet Med 2017; 19: 249-55.
- 8) Collisson EA, Bailey P, Chang DK, Biankin AV. Molecular subtypes of pancreatic cancer. Nat Rev Gastroenterol Hepatol 2019; 16: 207-20.
- 9) Hayashi H, Kohno T, Ueno H, et al. Utility of assessing the number of mutated KRAS, CDKN2A, TP53, and SMAD4 genes using a targeted deep sequencing assay as a prognostic biomarker for pancreatic cancer.Pancreas 2017; 46: 335-40.
- 10) Hayashi H, Tanishima S, Fujii K, et al. Genomic testing for pancreatic cancer in clinical practice as real-world evidence. Pancreatology 2018; 18: 647-54.
- 11) Hu ZI, Shia J, Stadler ZK, et al. Evaluating mismatch repair deficiency in pancreatic adenocarcinoma: challenges and recommendations. Clin Cancer Res 2018;24: 1326-36.
- 12) Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol 2018; 15: 731-47.
